Hudson Capital Management’s CorMedix CRMD Stock Holding History

Hudson Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,380	Closed	-$35K	–	81
2018 Q4	$35K	Hold	5,380	–	–	0.03%	75
2018 Q3	$26K	Hold	5,380	–	–	0.02%	76
2018 Q2	$6K	Hold	5,380	–	–	﹤0.01%	78
2018 Q1	$5K	Hold	5,380	–	–	﹤0.01%	76
2017 Q4	$14K	Buy	+5,380	New	+$15.4K	0.01%	85

Other funds holding CRMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EGI

EAM Global Investors Solana Beach, California $34.8M AUM 275.91% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Hudson Capital Management's CRMD Position: Q1 2019 in Review

Hudson Capital Management sold out of CorMedix (CRMD) in Q1 2019, closing a stake of 5,380 shares — an estimated $35K sold.

Hudson Capital Management first reported a position in CRMD in Q4 2017 and held it in 5 quarters. The position peaked at $35K in Q4 2018. 40 funds tracked by Wall St. Rank hold CRMD as of Q1 2019.

Hudson Capital Management reported no remaining CorMedix position as of Q1 2019 after selling out during the quarter.
Hudson Capital Management sold 5,380 CorMedix shares in Q1 2019, an estimated $35K.
Hudson Capital Management first reported a position in CorMedix in Q4 2017 and held it in 5 quarters.
Hudson Capital Management's CorMedix position peaked at $35K in Q4 2018.
40 funds tracked by Wall St. Rank held CorMedix as of Q1 2019.

Based on Hudson Capital Management's 13F filing for Q1 2019, filed 9 May 2019.